Navigation Links
Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years
Date:2/28/2011

LONDON, Feb. 28, 2011 /PRNewswire/ -- The staffs of Chiltern International Limited (Chiltern), a global contract research organization (CRO), and Spectratox Limited, celebrate the 25 year mark of their successful collaboration in Drug Phototoxicity.

Chiltern Early Phase and Spectratox have worked together using a validated and regulatory accepted in vivo human study method for the assessment of drug phototoxicity. The history of this collaboration can be traced through their multiple publications in peer reviewed journals.

"The success story of this methodology is not just measured in publications," stated Dr Brian Sanderson, Medical Director, Chiltern Early Phase. "It is measured in the success we have had in helping new drugs continue their developmental journey for areas of therapeutic need."

Professor James Ferguson, Head of the Academic Department of Dermatology, University of Dundee, and CEO of Spectratox, explained, "The evolution of randomized controlled trials has been in response to industry and regulatory requirements. Our trials, which tend to be conducted prior to Phase 3, produce data that defines the phototoxic risk in man in terms of severity and causal wavelengths as well as providing an understanding of the likelihood of ocular phototoxicity. Where phototoxicity is found, advice on protective measures to enable future development of the compound is an important aspect of our work."

Dr Sanderson added, "New study designs have been introduced to act as initial "screening" in man for drugs with potential phototoxicity. The new designs have evolved in response to the growing demand to assess this earlier in clinical drug development. The benefits are savings in both time and cost whilst remaining scientifically robust."

Glenn Kerkhof, Chiltern CEO, commented, "This 25 year collaboration is cause for celebration when we look back and realize the successes reached as well as what is presently being accomplished together. We very much look forward to what the next 25 years will bring in advancing drug development processes."

Company profilesAbout Chiltern:Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.

About Spectratox:Spectratox, although formally established in 2008, came about from a group of staff within the Photobiology Unit who had been collaborating with the Chiltern staff on drug phototoxicity work in Scotland since the mid 1980s. Together they developed an evidence-based methodology for studying phototoxicity in clinical volunteers. Professor Ferguson has 30 years experience advising on the need for such work.  The staff at Spectratox are also expert in pre-clinical laboratory data analysis; clinical 'healthy volunteer' studies and post-study testing; advice on product labelling and clinical management.  

Phototoxicity testing is carried out on the premises of the National Photobiology Unit, Ninewells Hospital and Medical School, a part of NHS Tayside (although Spectratox Ltd. is an independent company).  Further information: www.spectratox.co.uk.For More Information Contact:Natalie Chong, Marketing Director

Susan Ojanen, Marketing AssociateChiltern International Ltd.

Chiltern International Inc.UNITED KINGDOM

USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968 9533Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com
'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony
2. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
3. Luminex and Partners HealthCare Announce Collaboration Agreement
4. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
5. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
6. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
7. Ohio Business, Health Care Leaders Collaboration to Improve Patient Safety Results in Estimated Annual Savings of Nearly $13 Million
8. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
9. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
10. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
11. Veridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Mich. , April 28, 2016   ... . Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... has signed a definitive agreement to acquire Valley ... Specialty Pharmacy ("TNH"), a leading specialty pharmacy that ... Van Nuys, California . In 2015, TNH ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
Breaking Medicine Technology:
(Date:5/2/2016)... New York, NY (PRWEB) , ... May 02, 2016 , ... ... Highlighting the year’s best in pet gear and toys, leading product review site ... TTPM Pets Paw of Excellence Awards at their Spring Showcase at the Metropolitan ...
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... 2016 , ... According to an American Psychological Association article, the ... before the age of 18. Of those who survive, many still face effects as ... , In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board ... affordable prices announced today the outcome of their partnership with Yoloha Yoga- producers of ... “Roots Yoga Board.” , SUP yoga has seen a dramatic rise in popularity throughout ...
Breaking Medicine News(10 mins):